Author Topic: Impact of previous DMT on effectiveness, safety outcomes in PwMS treated w/Lemtrada  (Read 74 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest

From the Journal of Neurology, Neurosurgery and Psychiatry (April 5,  2021), "Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab":




https://jnnp.bmj.com/content/early/2021/03/11/jnnp-2020-325304.long


A summary of the findings is in Multiple Sclerosis News Today (April 5)--"Moving from Gilenya to Lemtrada May Not Be Optimal Choice, Study Says":


https://multiplesclerosisnewstoday.com/news-posts/2021/03/17/impact-of-previous-disease-modifying-treatment-on-effectiveness-and-safety-outcomes-among-patients-with-multiple-sclerosis-treated-with-alemtuzumab/
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
2 Replies
196 Views
Last post June 18, 2017, 04:06:52 pm
by agate
0 Replies
78 Views
Last post November 02, 2018, 07:33:40 am
by agate
0 Replies
118 Views
Last post April 22, 2019, 02:42:03 pm
by agate
0 Replies
52 Views
Last post February 22, 2020, 09:21:30 pm
by agate
0 Replies
24 Views
Last post July 06, 2022, 09:38:32 pm
by agate